Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab Long-term Extension in Crohn's Disease
NCT01199302Phase 2Terminated
- Sponsor
- Amgen
- Start
- Feb 2011
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of brodalumab in Crohn's disease, sponsored by Amgen. Started Feb 2011; status: terminated.
02
Drugs
brodalumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01199302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01199302.